Cardiac amyloidosis (CA) is caused by the deposition of misfolded aggregates of light chain (AL) or transthyretin (TTR) proteins, based on the precursor proteins, in the extracellular compartment of the myocardium. It causes a restrictive cardiomyopathy and poses significant challenges in both diagnosis and management. Radionuclide imaging techniques have emerged as pivotal tools in the evaluation of cardiac amyloidosis, offering insights into the pathological processes underlying this condition. Unlike anatomical imaging modalities, radionuclide imaging allows for the detection of molecular and functional abnormalities at early stages, enabling timely intervention with novel therapies recently introduced, that may result in improved patient outcomes and prognosis. In this chapter, we explore the principles, methodologies, and clinical applications of radionuclide imaging in the context of cardiac amyloidosis with emphasis on ATTR. We delve into the specific radiotracers and imaging modalities employed, their diagnostic accuracy, and their role in guiding therapeutic strategies. Furthermore, we discuss the evolving landscape of radionuclide imaging techniques, highlighting recent advances and their potential implications for the future diagnosis and management of this complex cardiac disorder. By examining the role of radionuclide imaging through a comprehensive lens, this chapter aims to provide clinicians and researchers with a thorough understanding of its utility in the context of cardiac amyloidosis, emphasizing its contribution to personalized patient care and improved clinical outcomes.